Sillajen Will Acquire Jennerex in $150M Deal
By Catherine Shaffer
Staff Writer
Staff Writer
Tuesday, November 26, 2013
An acquisition of Jennerex Inc. by Sillajen Inc. may be needed redemption for Jennerex’s recently troubled cancer immunotherapy, Pexa-Vec. The product failed to reach its primary endpoint of overall survival in a Phase IIb trial in September, resulting in a stock plummet for Jennerex’s European partner, Transgene SA.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.